Back to search results

Whole Exome Sequencing for Congestive Heart Failure in Breast Cancer Patients

This study is looking at DNA samples from people who have had breast cancer and received treatment with anthracycline and bevacizumab. Researchers are using a technique called whole exome sequencing to examine these DNA samples. The goal is to find specific changes in the DNA (called 'variants') that might explain why some patients develop congestive heart failure (CHF) after their breast cancer treatment, while others do not. By identifying these genetic changes, doctors hope to better understand the causes of CHF in this group of patients and potentially find ways to predict who might be at higher risk. This is an observational study, meaning researchers are studying existing samples rather than giving new treatments.

Study design
This is an observational study that plans to include 162 participants. It involves analyzing previously collected germline DNA samples.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to identify genetic variants at baseline, so ongoing follow-up is not specified for this part of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02610426

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting
Not specifiedAll AgesObservational
National Cancer Institute (NCI)
~162 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Laboratory Biomarker Analysis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identification of rare coding variants of large effect that predict the risk of CHF
Measured over Baseline

Conditions

Breast Carcinoma

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Bryan P Schneider · PRINCIPAL_INVESTIGATOR · Eastern Cooperative Oncology Group

Who to contact

Bryan P. Schneider
[email protected]
317-274-6473
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

European American patients with DNA available
European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

What this trial measures

  • Identification of rare coding variants of large effect that predict the risk of CHFBaseline

    Assessed by burden analysis.